• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy.酒精性肝硬化和腹膜恶性肿瘤所致腹水的纤溶活性
Gut. 1993 Aug;34(8):1120-2. doi: 10.1136/gut.34.8.1120.
2
Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass.体外循环期间心包形态和纤溶活性的变化。
J Thorac Cardiovasc Surg. 1993 Aug;106(2):339-45.
3
Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.酒精性肝硬化中的高纤溶状态:1型纤溶酶原激活物抑制物相对缺乏
Thromb Res. 2008;121(5):675-80. doi: 10.1016/j.thromres.2007.07.008. Epub 2007 Sep 17.
4
Fibrinolysis and the biliary tree.纤维蛋白溶解与胆管树
Gut. 1997 Jan;40(1):92-4. doi: 10.1136/gut.40.1.92.
5
Clinical value of components of the plasminogen activation system in ovarian cyst fluid.纤溶酶原激活系统各组分在卵巢囊肿液中的临床价值。
Anticancer Res. 2002 Jan-Feb;22(1A):275-82.
6
The fibrinolytic system in human ascites.
Scand J Gastroenterol. 1995 Nov;30(11):1101-7. doi: 10.3109/00365529509101614.
7
Peritoneovenous shunting for cirrhotic versus malignant ascites.用于肝硬化腹水与恶性腹水的腹腔静脉分流术。
Surg Gynecol Obstet. 1985 Sep;161(3):204-8.
8
Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta.尿激酶型纤溶酶原激活剂、纤溶酶原激活物抑制剂1型与活化蛋白C在人胎盘纤维蛋白溶解中的关系
Pol J Pharmacol. 1996 Mar-Apr;48(2):215-20.
9
Regulation and interactions in the activation of cell-associated plasminogen.细胞相关纤溶酶原激活中的调节与相互作用。
Cell Mol Life Sci. 2004 Nov;61(22):2840-58. doi: 10.1007/s00018-004-4230-9.
10
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.尿激酶型纤溶酶原激活物受体在肿瘤组织中的高浓度与卵巢癌患者的良好预后相关。
Int J Cancer. 2003 Nov 20;107(4):658-65. doi: 10.1002/ijc.11420.

引用本文的文献

1
Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma.人及小鼠卵巢癌中趋化素的活性形式升高。
Biomedicines. 2025 Apr 18;13(4):991. doi: 10.3390/biomedicines13040991.
2
Fibrinolysis in Dogs with Intracavitary Effusion: A Review.犬胸腔积液中的纤维蛋白溶解:综述
Animals (Basel). 2022 Sep 20;12(19):2487. doi: 10.3390/ani12192487.
3
Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.肝硬化伴腹水患者腹腔内凝血和纤溶激活。
Thromb Haemost. 2022 Mar;122(3):353-362. doi: 10.1055/a-1515-9529. Epub 2021 Jul 4.
4
Enhanced fibrinolysis detection in a natural occurring canine model with intracavitary effusions: Comparison and degree of agreement between thromboelastometry and FDPs, D-dimer and fibrinogen concentrations.腔内积液的自然发生犬模型中增强的纤维蛋白溶解检测:血栓弹力描记术与 FDPs、D-二聚体和纤维蛋白原浓度的比较和一致性程度。
PLoS One. 2019 Nov 14;14(11):e0225089. doi: 10.1371/journal.pone.0225089. eCollection 2019.
5
Hemostatic findings of pleural fluid in dogs and the association between pleural effusions and primary hyperfibrino(geno)lysis: A cohort study of 99 dogs.犬胸腔积液的止血检查结果及胸腔积液与原发性高纤维蛋白(原)溶解之间的关联:一项对99只犬的队列研究
PLoS One. 2018 Feb 20;13(2):e0192371. doi: 10.1371/journal.pone.0192371. eCollection 2018.
6
Hemostatic Findings in Ascitic Fluid: A Cross-Sectional Study in 70 Dogs.腹水的止血研究结果:70只犬的横断面研究
J Vet Intern Med. 2017 Jan;31(1):43-50. doi: 10.1111/jvim.14610. Epub 2016 Nov 16.
7
Reinfusion of ascites during hemodialysis as a treatment of massive refractory ascites and acute renal failure.血液透析期间腹水回输治疗大量难治性腹水和急性肾衰竭
Int J Nephrol Renovasc Dis. 2011;4:29-33. doi: 10.2147/IJNRD.S15792. Epub 2011 Feb 2.

本文引用的文献

1
Analysis of Twenty-three plasma proteins in ascites. The depletion of fibrinogen and plasminogen.腹水样本中23种血浆蛋白的分析。纤维蛋白原和纤溶酶原的消耗。
Ann Surg. 1980 Dec;192(6):738-42. doi: 10.1097/00000658-198012000-00008.
2
Complications after peritoneovenous shunting for ascites.腹水腹膜静脉分流术后的并发症。
Am J Surg. 1980 Jan;139(1):125-31. doi: 10.1016/0002-9610(80)90241-x.
3
Ascites-induced LeVeen shunt coagulopathy.腹水诱导的LeVeen分流术凝血障碍。
Ann Surg. 1983 Jul;198(1):91-5. doi: 10.1097/00000658-198307000-00018.
4
Management of malignant ascites with peritoneovenous shunting.采用腹腔静脉分流术治疗恶性腹水。
Am J Surg. 1983 Apr;145(4):455-7. doi: 10.1016/0002-9610(83)90039-9.
5
Ethyl alcohol enhances plasminogen activator secretion by endothelial cells.乙醇可增强内皮细胞纤溶酶原激活物的分泌。
JAMA. 1983 Aug 12;250(6):772-6.
6
Coagulant, fibrinolytic, and aggregating activity in ascitic fluid.腹水的凝血、纤溶及聚集活性。
Am J Gastroenterol. 1986 Jun;81(6):440-3.
7
Coagulopathy post peritoneovenous shunt.腹膜静脉分流术后凝血病
Ann Surg. 1987 Mar;205(3):305-11. doi: 10.1097/00000658-198703000-00015.
8
Plasminogen activators, tissue degradation, and cancer.纤溶酶原激活剂、组织降解与癌症
Adv Cancer Res. 1985;44:139-266. doi: 10.1016/s0065-230x(08)60028-7.
9
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.恶性和非恶性腹水中的纤溶酶原激活剂与纤溶酶原激活剂抑制剂
Eur J Clin Invest. 1988 Dec;18(6):595-9. doi: 10.1111/j.1365-2362.1988.tb01273.x.
10
Reduced human peritoneal plasminogen activating activity: possible mechanism of adhesion formation.人腹膜纤溶酶原激活活性降低:粘连形成的可能机制。
Br J Surg. 1989 Apr;76(4):382-4. doi: 10.1002/bjs.1800760422.

酒精性肝硬化和腹膜恶性肿瘤所致腹水的纤溶活性

Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy.

作者信息

Scott-Coombes D M, Whawell S A, Vipond M N, Crnojevic L, Thompson J N

机构信息

Department of Surgery, Hammersmith Hospital, London.

出版信息

Gut. 1993 Aug;34(8):1120-2. doi: 10.1136/gut.34.8.1120.

DOI:10.1136/gut.34.8.1120
PMID:8174965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1374366/
Abstract

Coagulopathy is a well recognised complication of peritoneovenous shunting for ascites. The relative contributions of primary fibrinolysis and disseminated intravascular coagulation remain controversial. Plasminogen activating activity was significantly lower in malignant ascites (n = 10, median < 0.02 (range < 0.02-1.26) IU/ml) than in alcoholic ascites (n = 10, 1.07 (0.30-1.49) IU/ml) (p < 0.05). Fibrinolytic activity was determined by a balance between tissue plasminogen activator and plasminogen activator inhibitor-1. There was no significant difference between the two groups in the concentration of tissue plasminogen activator (34 (12-64) ng/ml in malignant ascites v 29 (12-43) ng/ml in alcoholic ascites), but the concentration of plasminogen activator inhibitor-1 was significantly higher in malignant ascites (736 (213-1651) ng/ml) than in alcohol ascites (29 (12-43) ng/ml) (p < 0.05). Malignant ascites contained significantly higher concentrations of urokinase (0.7 (< 0.1-1.3) ng/ml v 0.2 (< 0.1-0.6) ng/ml in alcoholic ascites) and plasminogen activator inhibitor-2 (33 (< 6-140) ng/ml v 9 (< 6-28) ng/ml alcoholic ascites). The plasminogen activating activity of alcohol ascites may lead to primary fibrinolysis after peritoneovenous shunting. The considerably lower activity found in malignant ascites may explain why coagulopathy after shunting is less pronounced in this group of patients.

摘要

凝血功能障碍是腹水腹膜静脉分流术一种公认的并发症。原发性纤溶和弥散性血管内凝血的相对作用仍存在争议。恶性腹水(n = 10,中位数<0.02(范围<0.02 - 1.26)IU/ml)中的纤溶酶原激活活性显著低于酒精性腹水(n = 10,1.07(0.30 - 1.49)IU/ml)(p < 0.05)。纤溶活性由组织纤溶酶原激活物和纤溶酶原激活物抑制剂 - 1之间的平衡决定。两组之间组织纤溶酶原激活物浓度无显著差异(恶性腹水中为34(12 - 64)ng/ml,酒精性腹水中为29(12 - 43)ng/ml),但恶性腹水中纤溶酶原激活物抑制剂 - 1的浓度显著高于酒精性腹水(736(213 - 1651)ng/ml比29(12 - 43)ng/ml)(p < 0.05)。恶性腹水中尿激酶(0.7(<0.1 - 1.3)ng/ml比酒精性腹水中的0.2(<0.1 - 0.6)ng/ml)和纤溶酶原激活物抑制剂 - 2(33(<6 - 140)ng/ml比酒精性腹水中的9(<6 - 28)ng/ml)的浓度显著更高。酒精性腹水的纤溶酶原激活活性可能导致腹膜静脉分流术后原发性纤溶。在恶性腹水中发现的活性明显较低,这可能解释了为什么在这组患者中分流术后的凝血功能障碍不那么明显。